PRIMARY STUDY
Use of phytocanabinoids in animal models of Parkinson's disease: Systematic review
Key Findings: This analysis of the use of medicinal cannabis for the treatment of Prakinson's disease found that phytocannabinoids improved locomotor activity and involuntary movement and reduced catalepsy.
Type of Study: Meta-analysis
Study Sample Size: 23
Study Result: Positive
Research Location(s): Brazil
Year of Pub: 2024
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC), WIN-x Synthetic Cannabinoids, Fatty Acid Amide Hydrolase (FAAH), Tetrahydrocannabivarin (THCV)
Phytocannabinoid Source: Not Applicable
Chemotype: Chemotype I, Chemotype III
Receptors Studied: GPCR 55, TRPV1
Ligands Studied: Dopamine, Serotonin
DOSING DETAILS 
Study Dosing Objective: Effective Dose,
Established Protocol: Effective dose
Route of Administration: Injection, Oral (Ingestion)
Cannabinoid Ratio: (CBD) 0 
Dosage Form: Cannabidiol administered intraperitoneally
Dosing Regimen: Cannabidiol 30 mg/kg
Treatment Duration: 14 days
Citation: Alves ADF, et al. Use of phytocanabinoids in animal models of Parkinson's disease: Systematic review. Neurotoxicology. 2024; 105:34-44. doi: 10.1016/j.neuro.2024.08.002
Authors: Alves ADF, Dias FCR, Cadena PG, Silva-Jr VA
